Dolobid    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis3

28. Systemic amyloidosis    [ 212 clinical trials,   234 drugs,   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways]
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 212 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-001066-16-GB
(EUCTR)
25/08/201018/06/2010A randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosisA randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosis Hereditary neuropathic amyloidosis
MedDRA version: 11.;Level: LLT;Classification code 10019889;Term: Hereditary neuropathic amyloidosis
Trade Name: Dolobid
Product Name: diflunisal (dolobid)
INN or Proposed INN: diflunisal
Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. BerkNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140United Kingdom;Italy;Sweden
2EUCTR2006-001066-16-IT
(EUCTR)
30/01/200709/03/2007The effect of diflunisal IND 68092 on familial amyloidosis a randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects. - NDThe effect of diflunisal IND 68092 on familial amyloidosis a randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects. - ND familial amyloidosis
MedDRA version: 9.1;Level: LLT;Classification code 10016202;Term: Familial amyloidosis
Trade Name: Dolobid Boston University- The Amyloid Treatment and Research ProgramNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200United Kingdom;Italy;Sweden
3EUCTR2006-001066-16-SE
(EUCTR)
04/01/200709/11/2006The effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal TrialThe effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal Trial Familial Amyloid Polyneuropathy (FAP)Trade Name: Dolobid
Product Name: diflunisal (dolobid)
INN or Proposed INN: diflunisal
Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
John L. Berk, M.D.NULLNot RecruitingFemale: yes
Male: yes
200United Kingdom;Italy;Sweden